This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

It is a lovely day here in Monaghan, as they say in Ireland "I will say nothing till I hear more". Cheers balt.

Oh come on 049balt you're teasing us now. Let's have what you've got.

MS

I was thinking the same Mickey but even if 049balt said something amazing was about to happen would you buy some more! I might not have a big value holding compared to some but for me i`m in these in a big way.I can`t wait for good news to come out and like some people who have posted before bank some profit and get back in at a later date .
DB66

Can't see anything RNS like showing up until at least a few days after the Jersey presentation to allow any ditherers on board.

As for next news:-
Will it be Ru in P2?
Will it be Genvax Vaccine NHL P2 results?
Will it be a licence agreement for Ru with big pharma?
Will it be a licence agreement for Genvax NHL Vaccine with big pharma?
Will it be Genvax Stomach cancer vaccine entering P2?
Will it be Genvax Colon cancer vaccine entering P2?
Will it be Pineapple protease entering P2?
Will it be HIV update?
Will it be Hepatitis update?
Will it be Auto-Immune update?
Will it be a new technology joining the fold?

Who knows but could be any of the above.

Pete, being that I'm a greedy sod I'll settle for the lot. But as you say "who knows".

MS

I would say that 130p is looking like the support level for the short term prior to any forth coming news.

I am also in PRM, it is looking very good at the moment. cheers balt.

Level 2 is free today on advfn if anyone is interested.

seawallwalker - it is free for a wekk here - see the free trial thread on the Bulletin Boards. Plus you can try our terminal system as well.

Ian

Thanks Ian.

I was not aware, been busy this week.

As I am today

regards

is the free level 2 available on this stock? or only the free demo on barclays?

MEDICAL MARKETING TO BE GRANTED 3RD US PATENT FOR RUTHENIUM CANCER DRUG

The above from Greystones thread.

Up and away surely...........

Here it is.

Medical Marketing Int'l Group PLC
10 June 2005


FOR IMMEDIATE RELEASE 10th JUNE 2005

MMI TO BE GRANTED
THIRD US PATENT FOR RUTHENIUM ANTI CANCER THERAPIES

Further strengthens patent position for Ruthenium in world's biggest market

Medical Marketing International Group plc ('MMI') (AIM: MMG), the Cambridge,
UK-based pharmaceutical company focussed on the development of therapies for
cancer and infectious diseases, announces that it has been formally notified of
allowance of claims for a third patent by the US Patent Office for its
ruthenium-based anti-cancer therapies, being developed by MMI's wholly-owned
cancer therapy subsidiary Oncosense.

This further patent significantly strengthens MMI's protection for its ruthenium
library containing thousands of compounds. Earlier patents already protect the
Company's lead anti-cancer compounds that will enter into clinical development
in 2005 for key tumour types.

Commenting on today's news, David Best, Chairman of MMI Group said: 'This new
notification of grant of our third ruthenium patent in the USA enhances our
commercial position in the world's largest cancer therapy market.

The scope of our three US patents, when added to the two European patents where
we have already received notification of grant, strengthens our negotiating
position with commercial partners. This when added to the laboratory safety and
efficacy data that we already have, creates a ruthenium class of cancer
therapies which have significant potential.'

Tha she goes...............

More patents on the way, I'm sure.

patents changes nothing on the fundamental side, the company still does not have a lot cash, they still needs fresh fund, whatever the patents

Patents will lead to grants and funds.

And leverage when negotiating with the big pharmas. As they say "Every little bit helps".

MS

David Best is quoted saying that the new patent "strengthens our negotiating position with commercial partners".
I think most here know they are already talking to big pharma.
Like to see Ru in P2 soon.

Your not the only one Pete...

From the other side.

A0469514 - 10 Jun'05 - 11:41 - 5845 of 5853


These presentations in Dublin and Jersey are not for issuing new news but are to make the investment community aware of the potential in MMI. On here, we know enough so that most of us realise that the potential is massive. My research in the company satisfies me that the ruthenium compounds are an almost certain future blockbuster which, alone, will transform the company and its share price. Today's announcement strengthens that likelihood. Furthermore the Genvax trials look very likely to me to have a high probability of success, in which case, there could be two or three massive products resulting from that programme too. If David Best can get that feeling across to the institutions then the share price is sure to respond. You do not tend to get immediate share price action resulting from these presentations but we should see some benefit over the next few days.

Xylos